1. NF-κB
  2. NF-κB
  3. (-)-DHMEQ

(-)-DHMEQ (Synonyms: Dehydroxymethylepoxyquinomicin)

Cat. No.: HY-14645 Purity: 98.83% ee.: 99.50%
Handling Instructions

(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity.

For research use only. We do not sell to patients.

(-)-DHMEQ Chemical Structure

(-)-DHMEQ Chemical Structure

CAS No. : 287194-40-5

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 241 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 241 In-stock
Estimated Time of Arrival: December 31
Solid
2 mg USD 168 In-stock
Estimated Time of Arrival: December 31
5 mg USD 264 In-stock
Estimated Time of Arrival: December 31
10 mg USD 360 In-stock
Estimated Time of Arrival: December 31
25 mg USD 720 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 18 publication(s) in Google Scholar

Other Forms of (-)-DHMEQ:

Top Publications Citing Use of Products

    (-)-DHMEQ purchased from MCE. Usage Cited in: Biol Pharm Bull. 2017;40(10):1669-1677.

    A549 transfectants stably expressing RelB WT (A) are preincubated with various concentrations of (–)-DHMEQ for 1 h and then incubated with or without LTβ (25 ng/mL) for 2 h in the presence or absence of (−)-DHMEQ.

    (-)-DHMEQ purchased from MCE. Usage Cited in: Biol Pharm Bull. 2017;40(10):1669-1677.

    A549 transfectants stably expressing RelB (C144S) (B) are preincubated with various concentrations of (–)-DHMEQ for 1 h and then incubated with or without LTβ (25 ng/mL) for 2 h in the presence or absence of (−)-DHMEQ.

    (-)-DHMEQ purchased from MCE. Usage Cited in: Mol Cancer Ther. 2018 Jun;17(6):1303-1314.

    Effects of TNF-α/DHMEQ on the expression of NF-κB and AR as well as neoplastic transformation of urothelial cells. Western blotting of NF-κB/p65, p-NF-κB/p65, and AR, using proteins extracted from SVHUC-AR cells cultured with ethanol, TNF-α(20 ng/mL), or DHMEQ (15 µg/mL) for 6 hours.

    (-)-DHMEQ purchased from MCE. Usage Cited in: Mol Cancer Ther. 2018 Jun;17(6):1303-1314.

    Effects of NF-κB activation/inhibition on the expression of NF-κB and its downstream targets as well as AR in bladder cancer cells. Western blotting of NF-κB/p65, p-NF-κB/p65, and AR, using proteins extracted from UMUC3 cells cultured with ethanol (mock), TNF-α (20 ng/mL), or DHMEQ (15 µg/mL) for 6 hours.

    (-)-DHMEQ purchased from MCE. Usage Cited in: Mol Cells. 2018 Dec 31;41(12):1008-1015.

    NCI-H157 cells are pretreated with DHMEQ (10 or 20 μg/mL) for 2 h and then stimulated with PS-341 for 6 or 24 h. Nuclear proteins (6 h) and whole cell proteins (24 h) are isolated and subjected to Western blot analysis for p65, Lamin A/C, COX-2, and GAPDH.

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    (-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity[1][2][3].

    IC50 & Target[1]

    RelA

     

    RelB

     

    In Vitro

    (-)-DHMEQ (Dehydroxymethylepoxyquinomicin; 2-10 μg/mL; 12-48 hours) treatment significantly reduces the viability of all cell lines in a dose- and time-dependent manner, whereas the effect is not significant in a control cell line K562 without constitutive NF-κB activity[2].
    (-)-DHMEQ (10 μg/mL; 0-48 hours; TL-Om1, MT-1 and K562 cells) treatment significantly increases the Annexin V-positive cells in MT-1 and TL-Om1 cell lines[2].
    (-)-DHMEQ (10 μg/mL; 4-16 hours; MT-1 cells) treatment down-regulates Bcl-xL, Bcl-2, c-myc, cyclin D1, Rb, and p53, and up-regulates proapoptotic genes such as caspase-3, -8, and-9[2].
    (-)-DHMEQ treatment increases cells in G0 /G1 phase in a time-dependent manner, demonstrating antiproliferative effects of (-)-DHMEQ[2].
    (-)-DHMEQ binds to p65, cRel, RelB, and p50, but not to p52 at specific cysteine residues. (-)-DHMEQ inhibits not only DNA-binding of RelB, but also its interaction to importin. (-)-DHMEQ also induces instability of RelB[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[2]

    Cell Line: TL-Om1, MT-1, KK-1, ST-1 and K562 cells
    Concentration: 2 μg/mL, 5 μg/mL, 10 μg/mL
    Incubation Time: 12 hours, 24 hours, 48 hours
    Result: Significantly reduced the viability of all cell lines in a dose- and time-dependent manner.

    Apoptosis Analysis[2]

    Cell Line: TL-Om1, MT-1 and K562 cells
    Concentration: 10 μg/mL
    Incubation Time: 0 hours, 24 hours, 48 hours
    Result: Annexin V-positive cells were significantly increased after 24 to 48 hours.

    Western Blot Analysis[2]

    Cell Line: MT-1 cells
    Concentration: 10 μg/mL
    Incubation Time: 4 hours, 8 hours, 16 hours
    Result: Annexin V-positive cells were significantly increased after 24 to 48 hours.
    In Vivo

    (-)-DHMEQ (Dehydroxymethylepoxyquinomicin; 4 mg/kg or 12 mg/kg; intraperitoneal injection; on day 0 and 3 times a week; for one month; SCID mice) treatment shows a significant increase in the survival rate in mice[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male C.B17-scid/scid (5 weeks old) mice injected with MT-2 cells[2]
    Dosage: 4 mg/kg or 12 mg/kg
    Administration: Intraperitoneal injection; on day 0 and 3 times a week; for one month
    Result: Showed a significant increase in the survival rate in mice.
    Molecular Weight

    261.23

    Formula

    C₁₃H₁₁NO₅

    CAS No.
    SMILES

    O=C1[[email protected]@H](O2)[[email protected]@H]2[[email protected]@H](O)C(NC(C3=C(O)C=CC=C3)=O)=C1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    -20°C, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 32 mg/mL (122.50 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.8280 mL 19.1402 mL 38.2804 mL
    5 mM 0.7656 mL 3.8280 mL 7.6561 mL
    10 mM 0.3828 mL 1.9140 mL 3.8280 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      (-)-DHMEQ is prepared in DMSO and then diluted with saline[2].

    References

    Purity: 98.83% ee.: 99.50%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    (-)-DHMEQDehydroxymethylepoxyquinomicinNF-κBNuclear factor-κBNuclear factor-kappaBCysteinecovalentlyp65cRelRelBp50anti-inflammatoryanticancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    (-)-DHMEQ
    Cat. No.:
    HY-14645
    Quantity:
    MCE Japan Authorized Agent: